Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 5;25(1):37-53.
doi: 10.1093/neuonc/noac196.

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Khê Hoang-Xuan  1 , Martina Deckert  2 , Andrés J M Ferreri  3 , Julia Furtner  4 , Jaime Gallego Perez-Larraya  5 , Roger Henriksson  6 , Andreas F Hottinger  7 , Benjamin Kasenda  8 , Florence Lefranc  9 , Alexander Lossos  10 , Catherine McBain  11 , Matthias Preusser  12 , Patrick Roth  13 , Roberta Rudà  14   15 , Uwe Schlegel  16 , Riccardo Soffietti  15 , Carole Soussain  17 , Martin J B Taphoorn  18 , Valérie Touitou  19 , Michael Weller  13 , Jacoline E C Bromberg  20
Affiliations

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Khê Hoang-Xuan et al. Neuro Oncol. .

Abstract

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.

Keywords: chemotherapy; immunotherapy; primary CNS lymphoma; radiotherapy; treatment.

PubMed Disclaimer

References

    1. Deckert M BT, Ferry JA, et al. . Primary diffuse large B cell lymphoma of the CNS, World Health Organization Classification of Tumours of the Central Nervous System 2021. WHO Classification of Tumours Series (ed 5). Lyon, International Agency for Research on Cancer, 2021, pp 351–355
    1. Diamond C, Taylor TH, Im T, et al. : Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma. Curr HIV Res. 2006;4:375–8. - PubMed
    1. Ammassari A, Scoppettuolo G, Murri R, et al. : Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:365–71. - PubMed
    1. O’Neill BP, Decker PA, Tieu C, et al. : The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol. 2013;88:997–1000. - PMC - PubMed
    1. van der Meulen M, Dinmohamed AG, Visser O, et al. : Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia. 2017;31:1822–1825. - PubMed